112 related articles for article (PubMed ID: 29771169)
21. Can rash associated with HER1/EGFR inhibition be used as a marker of treatment outcome?
Pérez-Soler R
Oncology (Williston Park); 2003 Nov; 17(11 Suppl 12):23-8. PubMed ID: 14682120
[TBL] [Abstract][Full Text] [Related]
22. Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck.
Lassen P; Eriksen JG; Hamilton-Dutoit S; Tramm T; Alsner J; Overgaard J
J Clin Oncol; 2009 Apr; 27(12):1992-8. PubMed ID: 19289615
[TBL] [Abstract][Full Text] [Related]
23. Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB).
Jatoi A; Rowland K; Sloan JA; Gross HM; Fishkin PA; Kahanic SP; Novotny PJ; Schaefer PL; Johnson DB; Tschetter LK; Loprinzi CL
Cancer; 2008 Aug; 113(4):847-53. PubMed ID: 18543329
[TBL] [Abstract][Full Text] [Related]
24. Pharmacodynamic trial of nimotuzumab in unresectable squamous cell carcinoma of the head and neck: a SENDO Foundation study.
Rojo F; Gracias E; Villena N; Cruz T; Corominas JM; Corradino I; Cedeño M; Campas C; Osorio M; Iznaga N; Bellosillo B; Rovira A; Marsoni S; Gascon P; Serrano S; Sessa C; Crombet T; Albanell J
Clin Cancer Res; 2010 Apr; 16(8):2474-82. PubMed ID: 20371675
[TBL] [Abstract][Full Text] [Related]
25. Dosing to rash?--The role of erlotinib metabolic ratio from patient serum in the search of predictive biomarkers for EGFR inhibitor-mediated skin rash.
Steffens M; Paul T; Hichert V; Scholl C; von Mallek D; Stelzer C; Sörgel F; Reiser B; Schumann C; Rüdiger S; Boeck S; Heinemann V; Kächele V; Seufferlein T; Stingl J
Eur J Cancer; 2016 Mar; 55():131-9. PubMed ID: 26820683
[TBL] [Abstract][Full Text] [Related]
26. Relationship between skin rash and outcome in non-small-cell lung cancer patients treated with anti-EGFR tyrosine kinase inhibitors: a literature-based meta-analysis of 24 trials.
Petrelli F; Borgonovo K; Cabiddu M; Lonati V; Barni S
Lung Cancer; 2012 Oct; 78(1):8-15. PubMed ID: 22795701
[TBL] [Abstract][Full Text] [Related]
27. Polymorphisms of the epidermal growth factor receptor (EGFR) and survival in patients with advanced cancer of the head and neck (HNSCC).
Stoehlmacher-Williams J; Obermann L; Ehninger G; Goekkurt E
Anticancer Res; 2012 Feb; 32(2):421-5. PubMed ID: 22287728
[TBL] [Abstract][Full Text] [Related]
28. Zalutumumab in head and neck cancer.
Schick U; Gujral DM; Richards TM; Harrington KJ; Nutting CM
Expert Opin Biol Ther; 2012 Jan; 12(1):119-25. PubMed ID: 22171666
[TBL] [Abstract][Full Text] [Related]
29. Influence of allelic Variations of hypoxia-related and DNA repair genes on patient outcome and toxicity in head and neck cancer treated with radiotherapy plus cetuximab.
Muñoz C; Caballero M; Hakim S; Verger E; Grau JJ
Eur Arch Otorhinolaryngol; 2016 Aug; 273(8):2193-9. PubMed ID: 26245169
[TBL] [Abstract][Full Text] [Related]
30. The influence of epidermal growth factor receptor and tumor differentiation on the response to accelerated radiotherapy of squamous cell carcinomas of the head and neck in the randomized DAHANCA 6 and 7 study.
Eriksen JG; Steiniche T; Overgaard J;
Radiother Oncol; 2005 Feb; 74(2):93-100. PubMed ID: 15816106
[TBL] [Abstract][Full Text] [Related]
31. Skin rash as useful marker of erlotinib efficacy in NSCLC and its impact on clinical practice.
Fiala O; Pesek M; Finek J; Krejci J; Ricar J; Bortlicek Z; Benesova L; Minarik M
Neoplasma; 2013; 60(1):26-32. PubMed ID: 23067213
[TBL] [Abstract][Full Text] [Related]
32. Relationship between epidermal growth factor receptor status, p16(INK4A), and outcome in head and neck squamous cell carcinoma.
Young RJ; Rischin D; Fisher R; McArthur GA; Fox SB; Peters LJ; Corry J; Lim A; Waldeck K; Solomon B
Cancer Epidemiol Biomarkers Prev; 2011 Jun; 20(6):1230-7. PubMed ID: 21467228
[TBL] [Abstract][Full Text] [Related]
33. Does transfusion improve the outcome for HNSCC patients treated with radiotherapy? - results from the randomized DAHANCA 5 and 7 trials.
Hoff CM; Lassen P; Eriksen JG; Hansen HS; Specht L; Overgaard M; Grau C; Johansen J; Bentzen J; Andersen L; Evensen JF; Overgaard J
Acta Oncol; 2011 Oct; 50(7):1006-14. PubMed ID: 21790306
[TBL] [Abstract][Full Text] [Related]
34. Association between single nucleotide polymorphisms in the XRCC1 and RAD51 genes and clinical radiosensitivity in head and neck cancer.
Pratesi N; Mangoni M; Mancini I; Paiar F; Simi L; Livi L; Cassani S; Buglione M; Grisanti S; Almici C; Polli C; Saieva C; Magrini SM; Biti G; Pazzagli M; Orlando C
Radiother Oncol; 2011 Jun; 99(3):356-61. PubMed ID: 21704413
[TBL] [Abstract][Full Text] [Related]
35. Multicenter Phase II Study of Panitumumab in Platinum Pretreated, Advanced Head and Neck Squamous Cell Cancer.
Siano M; Molinari F; Martin V; Mach N; Früh M; Freguia S; Corradino I; Ghielmini M; Frattini M; Espeli V
Oncologist; 2017 Jul; 22(7):782-e70. PubMed ID: 28592616
[TBL] [Abstract][Full Text] [Related]
36. Resistance to EGFR inhibitors: molecular determinants and the enigma of head and neck cancer.
Morris LG; Chan TA
Oncotarget; 2011 Dec; 2(12):894-5. PubMed ID: 22248868
[No Abstract] [Full Text] [Related]
37. Incidence, risk and prognostic role of anti-epidermal growth factor receptor-induced skin rash in biliary cancer: a meta-analysis.
Wei F; Shin D; Cai X
Int J Clin Oncol; 2018 Jun; 23(3):443-451. PubMed ID: 29289981
[TBL] [Abstract][Full Text] [Related]
38. TGFbeta1 genetic polymorphism is associated with survival in head and neck squamous cell carcinoma independent of the severity of chemoradiotherapy induced mucositis.
Lundberg M; Saarilahti K; Mäkitie AA; Mattila PS
Oral Oncol; 2010 May; 46(5):369-72. PubMed ID: 20308003
[TBL] [Abstract][Full Text] [Related]
39. Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: a randomized phase II trial.
Martins RG; Parvathaneni U; Bauman JE; Sharma AK; Raez LE; Papagikos MA; Yunus F; Kurland BF; Eaton KD; Liao JJ; Mendez E; Futran N; Wang DX; Chai X; Wallace SG; Austin M; Schmidt R; Hayes DN
J Clin Oncol; 2013 Apr; 31(11):1415-21. PubMed ID: 23460709
[TBL] [Abstract][Full Text] [Related]
40. Risk of severe rash in cancer patients treated with EGFR tyrosine kinase inhibitors: a systematic review and meta-analysis.
Zhang X; Ran YG; Wang KJ
Future Oncol; 2016 Dec; 12(23):2741-2753. PubMed ID: 27522860
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]